Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 1/20 | 0.42 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.37 |
| ▸ | FLT1 | P17948 | 1/20 | 0.37 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.37 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.37 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.37 |
| ▸ | FLT4 | P35916 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | PDGFRB | P09619 | 13/20 | 0.36 |
| ▸ | EGFR | P00533 | 2/20 | 0.35 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8501657 | 0.87 | PDE4A (0.37) | KDREGFR | |
| SCHEMBL4518666 | 0.87 | PDGFRB (0.46) | CHEK1MAPK7FGFR1FLT1FGFR2 | |
| Hydrochloric Acid SCHEMBL8501633 | 0.86 | PDE4A (0.37) | KDREGFR | |
| Hydrochloric Acid SCHEMBL7206364 | 0.86 | CHEK1 (0.46) | CHEK1MAPK7FGFR1FLT1FGFR2 | |
| SCHEMBL8525763 | 0.83 | KDR (0.45) | CHEK1MAPK7FGFR1FLT1FGFR2 | |
| Acetic Acid SCHEMBL4677365 | 0.83 | EGFR (0.36) | MAPK7KDREGFR | |
| Hydrochloric Acid SCHEMBL7210163 | 0.83 | KDR (0.44) | CHEK1MAPK7FGFR1FLT1FGFR2 | |
| SCHEMBL7211883 | 0.82 | CHEK1 (0.53) | CHEK1MAPK7PDGFRB | |
| SCHEMBL4506547 | 0.82 | PDGFRB (0.53) | CHEK1MAPK7FGFR1FLT1FGFR2 | |
| SCHEMBL6671698 | 0.82 | KDR (0.35) | MAPK7KDREGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1458394-A1 | USE OF OXINDOLE DERIVATIVES IN THE TREATMENT OF DEMENTIA RELATED DISEASES, ALZHEIMER S DISEASE AND CONDITIONS ASSOCIATED WITH GLYCOGEN SYNTHASE KINASE-3 | AstraZeneca AB (SE) | 2004-09-22 | — | — | EP | claimed |
| WO-2003055492-A1 | USE OF OXINDOLE DERIVATIVES IN THE TREATMENT OF DEMENTIA RELATED DISEASES, ALZHEIMER'S DISEASE AND CONDITIONS ASSOCIATED WITH GLYCOGEN SYNTHASE KINASE-3 | ASTRAZENECA AB (SE) | 2003-07-10 | — | — | WO | claimed |
| EP-1458394-A1 | USE OF OXINDOLE DERIVATIVES IN THE TREATMENT OF DEMENTIA RELATED DISEASES, ALZHEIMER S DISEASE AND CONDITIONS ASSOCIATED WITH GLYCOGEN SYNTHASE KINASE-3 | AstraZeneca AB (SE) | 2004-09-22 | — | — | EP | disclosed |
| WO-2003055492-A1 | USE OF OXINDOLE DERIVATIVES IN THE TREATMENT OF DEMENTIA RELATED DISEASES, ALZHEIMER'S DISEASE AND CONDITIONS ASSOCIATED WITH GLYCOGEN SYNTHASE KINASE-3 | ASTRAZENECA AB (SE) | 2003-07-10 | — | — | WO | disclosed |